MA49456A - Composés et procédés pour le traitement de nafld et de nash - Google Patents
Composés et procédés pour le traitement de nafld et de nashInfo
- Publication number
- MA49456A MA49456A MA049456A MA49456A MA49456A MA 49456 A MA49456 A MA 49456A MA 049456 A MA049456 A MA 049456A MA 49456 A MA49456 A MA 49456A MA 49456 A MA49456 A MA 49456A
- Authority
- MA
- Morocco
- Prior art keywords
- nafld
- nash
- compounds
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762522045P | 2017-06-19 | 2017-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49456A true MA49456A (fr) | 2020-04-29 |
Family
ID=62875321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049456A MA49456A (fr) | 2017-06-19 | 2018-06-19 | Composés et procédés pour le traitement de nafld et de nash |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200129511A1 (fr) |
EP (1) | EP3641887A1 (fr) |
JP (1) | JP2020524181A (fr) |
MA (1) | MA49456A (fr) |
WO (1) | WO2018236896A1 (fr) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE366815T1 (de) | 1998-11-20 | 2007-08-15 | Arena Pharm Inc | Menschliche, an ein g-protein gekoppelter rezeptor rup3 ohne bekannten ligand |
BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
PL378295A1 (pl) | 2003-02-24 | 2006-03-20 | Arena Pharmaceuticals, Inc. | Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
RS20060018A (en) | 2003-07-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
CN1997640A (zh) | 2004-06-04 | 2007-07-11 | 艾尼纳制药公司 | 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗 |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
ES2354390T3 (es) | 2006-04-11 | 2011-03-14 | Arena Pharmaceuticals, Inc. | Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo. |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
EP2146210A1 (fr) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY |
US20100113480A1 (en) | 2008-10-30 | 2010-05-06 | Michael Reuman | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
US20100113479A1 (en) | 2008-10-30 | 2010-05-06 | Anusuya Choudhury | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
US20110015215A1 (en) | 2009-05-20 | 2011-01-20 | Paul Deghetto | Crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
US20100298362A1 (en) | 2009-05-20 | 2010-11-25 | Xun Li | Process for the preparation of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
SG11201705361PA (en) * | 2015-01-09 | 2017-08-30 | Gilead Apollo Llc | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
-
2018
- 2018-06-19 WO PCT/US2018/038319 patent/WO2018236896A1/fr unknown
- 2018-06-19 EP EP18740023.9A patent/EP3641887A1/fr not_active Withdrawn
- 2018-06-19 MA MA049456A patent/MA49456A/fr unknown
- 2018-06-19 US US16/624,198 patent/US20200129511A1/en not_active Abandoned
- 2018-06-19 JP JP2020519025A patent/JP2020524181A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2018236896A1 (fr) | 2018-12-27 |
US20200129511A1 (en) | 2020-04-30 |
JP2020524181A (ja) | 2020-08-13 |
EP3641887A1 (fr) | 2020-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA45192A (fr) | Traitement d'association | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA42420A (fr) | Vaccins pour le traitement et la prévention du cancer | |
MA41044A (fr) | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer | |
MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
MA47613A (fr) | Compositions et procédés de traitement du cancer | |
MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA52252A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer |